RecruitingNCT05508932

Atrial Fibrillation in Beta-Thalassemia


Sponsor

University Hospital of Ferrara

Enrollment

350 participants

Start Date

Sep 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The study aims to evaluate the clinical, laboratory and instrumental differences that exist between beta-thalassemia patients with atrial fibrillation and those not affected by arrhythmia.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how often patients with beta-thalassemia (an inherited blood disorder requiring regular blood transfusions) develop atrial fibrillation — an irregular heartbeat that can increase the risk of stroke. Because repeated transfusions can cause iron to build up in the heart, these patients are at higher risk for heart problems. **You may be eligible if...** - You have transfusion-dependent beta-thalassemia - You are being followed at the Cardiology Unit of the University Hospital of Ferrara - You have had both an ECG (heart tracing) and an echocardiogram (heart ultrasound) performed **You may NOT be eligible if...** - You are under 18 years of age - You are pregnant - You are unable to give informed consent - You have not had the required heart tests done Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Matteo Bertini

Ferrara, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05508932


Related Trials